Post-transplant Lymphoproliferative Disease - Pipeline Insight, 2024

Post-transplant Lymphoproliferative Disease - Pipeline Insight, 2024

DelveInsight’s, “Post-transplant Lymphoproliferative Disease - Pipeline Insight, 2024,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Post-transplant Lymphoproliferative Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Post-transplant Lymphoproliferative Disease Understanding

Post-transplant Lymphoproliferative Disease: Overview

Post-transplant lymphoproliferative disease (PTLD) is a rare, but well-known complication of solid organ transplants and hematopoietic stem cell transplantation. PTLD is related to the Epstein-Barr virus and immunosuppression therapy. People who receive these transplants are treated with drugs that suppress the activity of the immune system. Doctors must suppress the immune system to help the body accept the transplant and avoid rejection. Individuals receive these drugs at the time of the transplant (induction therapy) and must remain on these drugs for the rest of their lives (maintenance therapy). Immunosuppressive therapy leaves patients at a greater risk of developing infections and, in some people, of developing post-transplant lymphoproliferative disease. Early diagnosis and prompt treatment of these disorders are extremely important. The specific symptoms and severity of PTLD can vary greatly from one person to another. Some affected individuals develop a mild, noncancerous overgrowth of affected tissue, while other people can develop a cancerous, life-threatening form of lymphoma. The treatment of post-transplant lymphoproliferative disease is directed toward the specific symptoms that are apparent in each individual. Treatment may require the coordinated efforts of a team of specialists, including physicians who specialize in the diagnosis and treatment of cancer (medical oncologists), disorders of the blood and blood-forming tissues (hematologists), the use of radiation to treat cancers (radiation oncologists); transplant specialists; surgeons; oncology nurses; dietitians; and other healthcare professionals may need to systematically and comprehensively plan treatment. Psychosocial support for the entire family is essential as well.

""Post-transplant Lymphoproliferative Disease - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Post-transplant Lymphoproliferative Disease pipeline landscape is provided which includes the disease overview and Post-transplant Lymphoproliferative Disease treatment guidelines. The assessment part of the report embraces, in depth Post-transplant Lymphoproliferative Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Post-transplant Lymphoproliferative Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Post-transplant Lymphoproliferative Disease.
• In the coming years, the Post-transplant Lymphoproliferative Disease market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics that are working to assess challenges and seek opportunities that could influence Post-transplant Lymphoproliferative Disease R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• A detailed portfolio of major pharma players who are involved in fueling the Post-transplant Lymphoproliferative Disease treatment market. Several potential therapies for Post-transplant Lymphoproliferative Disease are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Post-transplant Lymphoproliferative Disease market size in the coming years.
• Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Post-transplant Lymphoproliferative Disease) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Post-transplant Lymphoproliferative Disease Emerging Drugs Chapters

This segment of the Post-transplant Lymphoproliferative Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Post-transplant Lymphoproliferative Disease Emerging Drugs

• Tabelecleucel: Atara Biotherapeutics

Tabelecleucel (tab‐cel®) is an off-the-shelf, allogeneic T-cell immunotherapy in development for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD). EBV+ PTLD is a type of lymphoma (cancer) that may occur after a solid organ transplant (SOT) or allogeneic hematopoietic cell transplant (HCT). Tab‐cel® has been granted Breakthrough Therapy Designation for EBV+ PTLD following allogeneic HCT by the U.S. Food and Drug Administration (FDA) and PRIME designation by the European Medicines Agency (EMA) for the same indication. Tab‐cel® has orphan drug designation in the U.S. and EU.

• Nana-Val (Nanatinostat and Valganciclovir): Viracta Therapeutics

Nanatinostat (VRx-3996) is an orally available histone deacetylase (HDAC) inhibitor being developed by Viracta. Nanatinostat selectively inhibits specific isoforms of Class I HDACs, an activity that is key to inducing viral genes epigenetically silenced in EBV-associated malignancies. Nanatinostat is currently being investigated in combination with the antiviral agent valganciclovir as an all-oral combination therapy, Nana-Val, in various subtypes of EBV-associated malignancies. Ongoing trials include a pivotal global, multicenter, open-label Phase 2 basket trial in multiple subtypes of relapsed/refractory EBV+ lymphoma (NAVAL-1) as well as a multinational Phase 1b/2 trial in patients with EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors.

Further product details are provided in the report……..

Post-transplant Lymphoproliferative Disease: Therapeutic Assessment

This segment of the report provides insights about the different Post-transplant Lymphoproliferative Disease drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Post-transplant Lymphoproliferative Disease

There are approx. 3+ key companies which are developing the therapies for Post-transplant Lymphoproliferative Disease. The companies which have their Post-transplant Lymphoproliferative Disease drug candidates in the most advanced stage, i.e. preregistration include, Atara Biotherapeutics.

• Phases

DelveInsight’s report covers around 3+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Post-transplant Lymphoproliferative Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous
• Molecule Type

Products have been categorized under various Molecule types such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Post-transplant Lymphoproliferative Disease: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Post-transplant Lymphoproliferative Disease therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Post-transplant Lymphoproliferative Disease drugs.

Post-transplant Lymphoproliferative Disease Report Insights

• Post-transplant Lymphoproliferative Disease Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Post-transplant Lymphoproliferative Disease Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Post-transplant Lymphoproliferative Disease drugs?
• How many Post-transplant Lymphoproliferative Disease drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Post-transplant Lymphoproliferative Disease?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Post-transplant Lymphoproliferative Disease therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Post-transplant Lymphoproliferative Disease and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Atara Biotherapeutics
• Viracta Therapeutics
• bluebird bio
• Moderna

Key Products

• Tabelecleucel
• Nana-Val
• Autologous Epstein-Barr virus-specific T-cell therapy
• mRNA-1195